Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$19.61MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jeffrey S. Hackman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 35
- Beta
- 1.21
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 6.52
Financials
Revenue
$19.61M+11434.1%Net Income
$4.64MEBITDA
$5.00MFree Cash Flow
$6.68MEPS (diluted)
$0.12Shares Outstanding (diluted)
38.08M+198.3%Operating Expenses
$14.12MCash & Debt
$48.68MReturn of Capital
$0.00Revenue by Segment (annual)
$170.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.64M | $-9.74M | $-0.36 |
| 2024 | $47.54M | $-436.0K | $-0.02 |
| 2023 | $21.25M | $-16.05M | $-0.60 |
| 2022 | $1.53M | $-23.71M | $-0.95 |
| 2021 | $0.00 | $-17.35M | $-0.67 |
| 2020 | $170.0K | $-18.11M | $-0.76 |
| 2019 | $0.00 | $-13.07M | $-0.63 |
| 2018 | $0.00 | $-9.89M | $-0.52 |
| 2017 | $0.00 | $-7.05M | $-0.47 |
| 2016 | $0.00 | $-2.79M | $-0.22 |
| 2015 | $0.00 | $-659.0K | $-0.06 |
| 2014 | $0.00 | $-2.18M | $-0.22 |
| 2013 | $0.00 | $1.84M | $0.19 |
| 2012 | $0.00 | $-5.16M | $-0.63 |
Valuation
FENChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
163+441.67%Social Signal Score
Mentions (6)
- Newszacks.com·9d ago·Positive
What Makes Adherex Technologies (FENC) a New Strong Buy Stock Adherex Technologies (FENC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·9d ago·Neutral
How Much Upside is Left in Adherex Technologies (FENC)? Wall Street Analysts Think 57.8% The consensus price target hints at a 57.8% upside potential for Adherex Technologies (FENC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
View source ↗ - Newsglobenewswire.com·16d ago·Neutral
…Report Third Quarter 2026 Financial Results on November 12, 2026 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, November 12, 2026. Management will host a conference call and webcast that day to discuss the Company's financial a…
View source ↗ - Newsglobenewswire.com·66d ago·Negative
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026 ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
Adherex Technologies Q2 Earnings Call Highlights Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
View source ↗ - Newszacks.com·103d ago·Neutral
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
View source ↗
Earnings
Tue, Mar 23(in 4 months)
Consensus estimate $0.16 per share
Typical surprise +66.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$0.12 vs $0.10beat
- Tue, Aug 11$0.05 vs $0.02beat
- Thu, May 14$0.01 vs $-0.02beat
- Tue, Mar 24$-0.17 vs $0.03miss
- Thu, Nov 13$-0.02 vs $-0.08beat
- Thu, Aug 14$-0.11 vs $-0.06miss
Estimates and results for FENC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FENC officers and directors.
- Bought
- —
- Sold
- $1.8m
0 trades
10 trades
- Brughera Marco Mariasold
- Raykov Rostysold
- Sayad Pierre Sargissold
- Andrade Robertsold
- Raykov Rostysold
- Raykov Rostysold
- Raykov Rostysold
- Rallis Chris Asold
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FENC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
